Paper36909127
Human Epidermal Growth Factor Receptor 2 (HER2) Expression by Immunohistochemistry and Its Clinical Significance in Hepatocellular Carcinoma: A Single-Center Analysis.
Magalhães D and 3 others. Cureus, 2023. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. Human Epidermal Growth Factor Receptor 2 (HER2) Expression by Immunohistochemistry and Its Clinical Significance in Hepatocellular Carcinoma: A Single-Center Analysis. Papers, record 36909127. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36909127
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Human Epidermal Growth Factor Receptor 2 (HER2) Expression by Immunohistochemistry and Its Clinical Significance in Hepatocellular Carcinoma: A Single-Center Analysis.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References57
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 11900227 | HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity. | Cancer | 2002 | https://conductscience.org/library/papers/11900227 | PubMed |
| 2 | 31876547 | Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting. | Curr Opin Oncol | 2020 | https://conductscience.org/library/papers/31876547 | PubMed |
| 3 | 29018945 | [Nuclear Her2 expression in hepatocytes in liver disease]. | Pathologe | 2017 | https://conductscience.org/library/papers/29018945 | PubMed |
| 4 | 35148934 | Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer. | Breast | 2022 | https://conductscience.org/library/papers/35148934 | PubMed |
| 5 | 32402160 | Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32402160 | PubMed |
| 6 | 22153890 | Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. | Lancet Oncol | 2012 | https://conductscience.org/library/papers/22153890 | PubMed |
| 7 | 11597398 | The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. | Eur J Cancer | 2001 | https://conductscience.org/library/papers/11597398 | PubMed |
| 8 | 35665782 | Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. | N Engl J Med | 2022 | https://conductscience.org/library/papers/35665782 | PubMed |
| 9 | 11248153 | Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | N Engl J Med | 2001 | https://conductscience.org/library/papers/11248153 | PubMed |
| 10 | 7894139 | C-erb-B-2 oncoprotein and epidermal growth factor receptor in human hepatocellular carcinoma: an immunohistochemical study. | Histol Histopathol | 1994 | https://conductscience.org/library/papers/7894139 | PubMed |
| 11 | 1374219 | Immunoreactivity for c-erbB-2 oncopeptide in benign and malignant diseases of the liver. | Am J Clin Pathol | 1992 | https://conductscience.org/library/papers/1374219 | PubMed |
| 12 | 25279210 | Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: A meta-analysis with comparison of different types of hepatitis. | Mol Clin Oncol | 2014 | https://conductscience.org/library/papers/25279210 | PubMed |
| 13 | 20728210 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. | Lancet | 2010 | https://conductscience.org/library/papers/20728210 | PubMed |
| 14 | 31825192 | Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. | N Engl J Med | 2020 | https://conductscience.org/library/papers/31825192 | PubMed |
| 15 | 18650514 | Sorafenib in advanced hepatocellular carcinoma. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18650514 | PubMed |
| 16 | 15858121 | Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma. | J Clin Pathol | 2005 | https://conductscience.org/library/papers/15858121 | PubMed |
| 17 | 21741829 | Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. | Eur J Cancer | 2011 | https://conductscience.org/library/papers/21741829 | PubMed |
| 18 | 10880430 | The ErbB signaling network: receptor heterodimerization in development and cancer. | EMBO J | 2000 | https://conductscience.org/library/papers/10880430 | PubMed |
| 19 | 16557381 | Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. | J Cancer Res Clin Oncol | 2006 | https://conductscience.org/library/papers/16557381 | PubMed |
| 20 | 29420221 | Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study. | Clin Cancer Res | 2018 | https://conductscience.org/library/papers/29420221 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41710748 | Peptide-Functionalized Liposomal Nanocarriers for Targeted Therapy of Liver Fibrosis and Hepatocellular Carcinoma: Design, Mechanisms, and Clinical Prospects. | ACS Pharmacol Transl Sci | 2026 | https://conductscience.org/library/papers/41710748 | PubMed |
| 41641648 | A Clinical Guidance for the Management of Patients With Hepatoid Adenocarcinoma and A Case Series. | Cancer Med | 2026 | https://conductscience.org/library/papers/41641648 | PubMed |
| 40599803 | Decoding the therapeutic mechanism of Conocarpus lancifolius in hepatocellular carcinoma: network pharmacology, molecular docking, and LC-MS QTOF insights. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40599803 | PubMed |
| 40028484 | Liquid biopsy kinetics and detection of ERBB2 amplification/HER2-positivity in refractory hepatocellular carcinoma. | J Liq Biopsy | 2023 | https://conductscience.org/library/papers/40028484 | PubMed |
| 39524833 | Network pharmacology and bioinformatic integrative analysis reveals candidate gene targets and potential therapeutic of East Kalimantan propolis against hepatocellular carcinoma. | Heliyon | 2024 | https://conductscience.org/library/papers/39524833 | PubMed |
| 39335117 | Prognostic and Predictive Roles of HER2 Status in Non-Breast and Non-Gastroesophageal Carcinomas. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39335117 | PubMed |
| 37293382 | Bioinformatics and network pharmacology-based study to elucidate the multi-target pharmacological mechanism of the indigenous plants of Medina valley in treating HCV-related hepatocellular carcinoma. | Saudi Pharm J | 2023 | https://conductscience.org/library/papers/37293382 | PubMed |
Genes11
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AFP | 174 | PubTator's text mining | https://conductscience.org/library/genes/174 | NCBI Gene |
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| EGF | 1950 | PubTator's text mining | https://conductscience.org/library/genes/1950 | NCBI Gene |
| ELAVL1 | 1994 | PubTator's text mining | https://conductscience.org/library/genes/1994 | NCBI Gene |
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| FGF19 | 9965 | PubTator's text mining | https://conductscience.org/library/genes/9965 | NCBI Gene |
| MTOR | 2475 | PubTator's text mining | https://conductscience.org/library/genes/2475 | NCBI Gene |
| TERT | 7015 | PubTator's text mining | https://conductscience.org/library/genes/7015 | NCBI Gene |
| TP53 | 7157 | PubTator's text mining | https://conductscience.org/library/genes/7157 | NCBI Gene |
| TXK | 7294 | PubTator's text mining | https://conductscience.org/library/genes/7294 | NCBI Gene |
| VEGFA | 7422 | PubTator's text mining | https://conductscience.org/library/genes/7422 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36909127
GET https://conductscience.org/api/papers/v1/36909127/references?page=2